<DOC>
	<DOCNO>NCT01617148</DOCNO>
	<brief_summary>This study examine use Aflibercept patient exudative macular degeneration require intravitreal injection . Patients follow 12 month .</brief_summary>
	<brief_title>Wet Macular Degeneration Study Compare Ranibizumab Bevacizumab Aflibercept</brief_title>
	<detailed_description>The purpose study examine use Aflibercept patient previously treat Ranibizumab Bevacizumab exudative macular degeneration . Specifically , examine effect macular degeneration , measure SDOCT ( Spectral Domain Optical Coherence Tomography ) ETDRS ( Early Treatment Diabetic Retinopathy Study ) visual acuity . This prospective study patient receive intravitreal injection Aflibercept time treatment .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Inclusion Criteria A subject must meet follow criterion eligible inclusion study : 1 . Signed Informed Consent . 2 . Men woman ≥ 50 year age . 3 . Active primary subfoveal CNV lesion secondary AMD , include juxtafoveal lesion affect fovea evidence historical OCTs angiogram study eye . 4 . CNV must least 50 % total lesion size either previous current angiogram . 5 . ETDRS bestcorrected visual acuity : 20/25 20/320 ( letter score 73 25 ) study eye . 6 . Willing , commit , able return ALL clinic visit complete study related procedure . 7 . At least one injection Ranibizumab Bevacizumab within 3 month enrollment active exudative AMD . 8 . Active need antiVEGF therapy study entry base follow criterion : 1 . Presence fluid either OCT clinical examination ( defined intraretinal , cystoid , subretinal , worsen pigment epithelial detachment ) 2 . Presence new hemorrhage clinical examination Exclusion Criteria A subject meet follow criterion exclude study : 1 . Any prior concomitant therapy another investigational agent treat neovascular AMD study eye , except dietary supplement vitamin . 2 . Prior systemic antiVEGF therapy , investigational FDA/Health Canada approve , allow 3 month prior first dose , allow study . 3 . Presence retinal pigment epithelial tear rip involve macula study 4 . History vitreous hemorrhage within 4 week prior Visit 1 study eye . 5 . Presence cause CNV , include pathologic myopia ( spherical equivalent 8 diopter negative , axial length 25 mm ) , ocular histoplasmosis syndrome , angioid streak , choroidal rupture , multifocal choroiditis study eye . 6 . History clinical evidence diabetic retinopathy , diabetic macular edema vascular disease affect retina , AMD , either eye . 7 . Prior vitrectomy study eye . 8 . History retinal detachment treatment surgery retinal detachment study eye . 9 . Any history macular hole stage 2 study eye . 10 . Any intraocular periocular surgery within 3 month Day 1 study eye , except lid surgery , may take place within 1 month day 1 , long 's unlikely interfere injection . 11 . Prior trabeculectomy filtration surgery study eye . 12 . Uncontrolled glaucoma baseline evaluation ( defined intraocular pressure ≥25 mmHg despite treatment antiglaucoma medication ) study eye . 13 . Active intraocular inflammation either eye . 14 . Active ocular periocular infection either eye . 15 . Any ocular periocular infection within last 2 week prior Screening either eye . 16 . Any history uveitis either eye . 17 . Active scleritis episcleritis either eye . 18 . Presence history scleromalacia either eye . 19 . Aphakia pseudophakia absence posterior capsule ( unless occur result yttrium aluminum garnet [ YAG ] posterior capsulotomy ) study eye . 20 . Previous therapeutic radiation region study eye . 21 . History corneal transplant corneal dystrophy study eye . 22 . Significant medium opacity , include cataract , study eye might interfere visual acuity , assessment safety , fundus photography . 23 . Any concurrent intraocular condition study eye ( e.g . cataract ) , opinion investigator , could require either medical surgical intervention 52 week study period . 24 . Any concurrent ocular condition study eye , opinion investigator , could either increase risk subject beyond expect standard procedure intraocular injection , otherwise may interfere injection procedure evaluation efficacy safety . 25 . Participation subject clinical study within 12 week prior Day 1 . 26 . Any systemic investigational agent past 3 month prior Day 1 . 27 . The use long act intraocular steroid photodynamic therapy 6 month prior day 1 . 28 . Any history allergy povidone iodine . 29 . Pregnant breastfeed woman 30 . Women childbearing potential* unwilling practice adequate contraception study ( adequate contraceptive measure include stable use oral contraceptive prescription pharmaceutical contraceptive 2 menstrual cycle prior screen ; intrauterine device [ IUD ] ; bilateral tubal ligation ; vasectomy ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam , jelly ) *Postmenopausal woman must amenorrheic least 12 month order consider child bear potential . Pregnancy test contraception require woman document hysterectomy tubal ligation .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Exudative Macular Degeneration</keyword>
	<keyword>Aflibercept</keyword>
</DOC>